Labarta, J.I. orcid.org/0000-0003-2832-2266, Dimitri, P. orcid.org/0000-0001-7625-6713, Keiser, M. orcid.org/0000-0001-6870-6585 et al. (2 more authors) (2023) Evaluating the usefulness and ease of use of a next-generation–connected drug delivery device for growth hormone therapy: qualitative study of health care professionals’ perceptions. JMIR Human Factors, 10. e46893. ISSN 2292-9495
Abstract
Background:
Digital solutions targeting children’s health have become an increasingly important element in the provision of integrated health care. For the treatment of growth hormone deficiency (GHD), a unique connected device is available to facilitate the delivery of recombinant human growth hormone (r-hGH) by automating the daily injection process and collecting injection data such that accurate adherence information is available to health care professionals (HCPs), caregivers, and patients. The adoption of such digital solutions requires a good understanding of the perspectives of HCPs as key stakeholders because they leverage data collection and prescribe these solutions to their patients.
Objective:
This study aimed to evaluate the third generation of the easypod device (EP3) for the delivery of r-hGH treatment from the HCP perspective, with a focus on perceived usefulness and ease of use.
Methods:
A qualitative study was conducted, based on a participatory workshop conducted in Zaragoza, Spain, with 10 HCPs experienced in the management of pediatric GHD from 7 reference hospitals in Spain. Several activities were designed to promote discussion among participants about predefined topics based on the Technology Acceptance Model and the Unified Theory of Acceptance and Use of Technology to provide their perceptions about the new device.
Results:
Participants reported 2 key advantages of EP3 over previous easypod generations: the touch screen interface and the real-time data transmission functionality. All participants (10/10, 100%) agreed that the new device should be part of a digital health ecosystem that provides complementary functionalities including data analysis.
Conclusions:
This study explored the perceived value of the EP3 autoinjector device for the treatment of GHD by HCPs. HCPs rated the new capabilities of the device as having substantial improvements and concluded that it was highly recommendable for clinical practice. EP3 will enhance decision-making and allow for more personalized care of patients receiving r-hGH.
JMIR Hum Factors 2023;10:e46893
doi:10.2196/46893
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © José I Labarta, Paul Dimitri, Matthew Keiser, Ekaterina Koledova, Octavio Rivera-Romero. Originally published in JMIR Human Factors (https://humanfactors.jmir.org), 02.08.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Human Factors, is properly cited. |
Keywords: | connected health; growth hormone deficiency; mobile phone; participatory health informatics; recombinant human growth hormone; technology acceptance |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 30 Nov 2023 12:19 |
Last Modified: | 30 Nov 2023 12:19 |
Status: | Published |
Publisher: | JMIR Publications Inc. |
Refereed: | Yes |
Identification Number: | 10.2196/46893 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:205701 |